Barclays
CBAY

Barclays’s Cymabay Therapeutics CBAY Stock Holding History

Barclays’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-30,000
Closed -$709K – 5446
2023
Q4 		$709K Sell
30,000
-53,800
-64% -$958K ﹤0.01% 3670
2023
Q3 		$1.25M Buy
+83,800
New +$1.11M ﹤0.01% 2179

Other funds holding CBAY

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Barclays's CBAY Position: Q1 2024 in Review

Barclays sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 190,332 shares — an estimated $4.5M sold.

Barclays first reported a position in CBAY in Q3 2014 and held it in 30 quarters. The position peaked at $4.5M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

  • Barclays reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Barclays sold 190,332 Cymabay Therapeutics shares in Q1 2024, an estimated $4.5M.
  • Barclays first reported a position in Cymabay Therapeutics in Q3 2014 and held it in 30 quarters.
  • Barclays's Cymabay Therapeutics position peaked at $4.5M in Q4 2023.
  • 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Barclays's 13F filing for Q1 2024, filed 15 May 2024.